Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia (AML) Market

Acute Myeloid Leukemia (AML), also known as acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia, is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues.


Acute Myeloid Leukemia signs and symptoms include fever, bone pain, fatigue, shortness of breath, pale skin, frequent infections, easy bruising, unusual bleeding.


AML is one of the most common types of leukemia in adults, and even being rare, it is the leading cause of leukemia-related deaths. It is found to be slightly more common among men as compared to women.


Acute Myeloid Leukemia (AML) Epidemiology Segmentation


  • Total Acute Myeloid Leukemia Diagnosed Cases
  • Gender-specific Acute Myeloid Leukemia Cases
  • Age-specific Acute Myeloid Leukemia Cases
  • Genetic Mutation-specific Acute Myeloid Leukemia Cases


Acute Myeloid Leukemia (AML) Epidemiology Insights


  • The total Acute Myeloid Leukemia incident population in the 7MM in the year 2021 was observed to be 42,301 cases. 
  • The number of Acute Myeloid Leukemia cases in 2020 in the United States was observed to be 20,145, whereas 1,955 cases in Spain.
  • Gender-specific Acute Myeloid Leukemia cases in the US in 2020 were observed to be 10,475 cases in males whereas 9,670 cases in females were estimated.


Acute Myeloid Leukemia (AML) Market Insights


The market size of Acute Myeloid Leukemia in the United States was found to be USD 1,251.1 million in the year 2020.  


Acute Myeloid Leukemia (AML) Market Drivers


  • Imminent launches
  • An upsurge in research and development
  • Enriched understanding
  • Increased incidence


Acute Myeloid Leukemia (AML) Market Barriers


  • High cost of therapy
  • Toxic therapies
  • Limitation in designing clinical trials
  • Low survival rate


Acute Myeloid Leukemia (AML) Emerging Drugs


  • Inqovi (ASTX727 [Decitabine and cedazuridine]).
  • Dociparstat sodium (DSTAT, CX-01)
  • Pevonedistat (TAK-924, MLN4924)
  • Devimistat (CPI-613)
  • Radgocitabine (DFP-10917)
  • Uproleselan
  • Bemcentinib
  • Flotetuzumab (MGD006)
  • SNDX-5613
  • Crenolanib
  • Olutasidenib (FT-2102)
  • Galinpepimut-S
  • Iomab-B, and several others. 


Acute Myeloid Leukemia (AML) Key Pharma Players


  • AstraZeneca
  • Astex Pharmaceuticals, Inc.
  • Chimerix
  • Takeda
  • Rafael Pharmaceuticals Inc.
  • Delta-Fly Pharma
  • GlycoMimetics Incorporated
  • BerGenBio ASA
  • MacroGenics
  • Syndax Pharmaceuticals
  • Arog Pharmaceuticals
  • Forma Therapeutics
  • Sellas Life Sciences Group
  • Actinium Pharmaceuticals, and several others.